UY31945A - Una nueva sal de glicinato de metformina para el control de la glucosa en sangre - Google Patents
Una nueva sal de glicinato de metformina para el control de la glucosa en sangreInfo
- Publication number
- UY31945A UY31945A UY0001031945A UY31945A UY31945A UY 31945 A UY31945 A UY 31945A UY 0001031945 A UY0001031945 A UY 0001031945A UY 31945 A UY31945 A UY 31945A UY 31945 A UY31945 A UY 31945A
- Authority
- UY
- Uruguay
- Prior art keywords
- salt
- metformin
- glycinate
- glucose
- blood
- Prior art date
Links
- KOFRCHIVYXPUNL-UHFFFAOYSA-N 2-aminoacetic acid;3-(diaminomethylidene)-1,1-dimethylguanidine Chemical class NCC(O)=O.CN(C)C(=N)N=C(N)N KOFRCHIVYXPUNL-UHFFFAOYSA-N 0.000 title abstract 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 2
- 239000008280 blood Substances 0.000 title abstract 2
- 210000004369 blood Anatomy 0.000 title abstract 2
- 239000008103 glucose Substances 0.000 title abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000004471 Glycine Substances 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 238000005342 ion exchange Methods 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 229950007228 metformin glycinate Drugs 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención se refiere a la síntesis de nueva sal de Glicinato 1,1-dimetilbiguanida, Glicinato de Metformina, controla la glucosa sanguinea con pronunciado efecto farmacológico. esta sal tiene un contraión con efectos hipoglucemiantes por sí mismo; exhibe una mejor absorción, alcanzando una concentración plasmática más alta que otras sales.La síntesis parte de clorhidrato de metfomina liberando el contraión hidrocloruro mediante intercambio iónico, la metformina liberada es disuelta adicionando glicina, al producto concentrado por calor se adiciona un solvente orgánico, creando insolubilidad, favoreciendo cristalización en medio saturado, el exceso de glicina precipita y se obtiene la sal glicinato de metformina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2008/002665 WO2009144527A1 (en) | 2008-06-26 | 2008-06-26 | A new metformin glycinate salt for blood glucose control |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY31945A true UY31945A (es) | 2010-01-05 |
Family
ID=40383805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001031945A UY31945A (es) | 2008-06-26 | 2009-06-26 | Una nueva sal de glicinato de metformina para el control de la glucosa en sangre |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8703183B2 (es) |
| EP (1) | EP2303838B1 (es) |
| JP (1) | JP5551691B2 (es) |
| KR (1) | KR101522066B1 (es) |
| CN (1) | CN102159539B (es) |
| AR (1) | AR074159A1 (es) |
| AU (1) | AU2008357111B2 (es) |
| BR (1) | BRPI0822909B8 (es) |
| CA (1) | CA2729035C (es) |
| CL (1) | CL2009001484A1 (es) |
| CY (1) | CY1115098T1 (es) |
| DK (1) | DK2303838T3 (es) |
| EC (1) | ECSP10010719A (es) |
| ES (1) | ES2450148T3 (es) |
| HR (1) | HRP20140194T1 (es) |
| JO (1) | JO2884B1 (es) |
| MA (1) | MA32418B1 (es) |
| MX (1) | MX2011000135A (es) |
| NI (1) | NI201000234A (es) |
| PE (1) | PE20100257A1 (es) |
| PL (1) | PL2303838T3 (es) |
| PT (1) | PT2303838E (es) |
| SI (1) | SI2303838T1 (es) |
| TN (2) | TN2010000607A1 (es) |
| UY (1) | UY31945A (es) |
| WO (1) | WO2009144527A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2303838T3 (en) | 2008-06-26 | 2014-03-03 | Silanes Sa De Cv Lab | New metforminglycinatsalt for blood glucose control |
| US9382187B2 (en) | 2012-07-10 | 2016-07-05 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
| US8765811B2 (en) | 2012-07-10 | 2014-07-01 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
| US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
| US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| CN103263405B (zh) * | 2013-05-08 | 2015-04-22 | 南京医科大学 | 用于治疗糖尿病的药物组合物及其应用 |
| US9815777B2 (en) | 2013-09-22 | 2017-11-14 | Jiva Pharma, Inc. | Metformin salts to treat Type2 diabetes |
| US9898585B2 (en) | 2014-01-31 | 2018-02-20 | Aseko, Inc. | Method and system for insulin management |
| US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
| US9505709B2 (en) | 2014-05-05 | 2016-11-29 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
| US10166246B2 (en) | 2014-05-27 | 2019-01-01 | City Of Hope | TGR5 agonist complexes for treating diabetes and cancer |
| US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
| EA201692548A1 (ru) | 2014-06-18 | 2017-10-31 | ТЕТИС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи | Минеральные аминокислотные комплексы активных веществ |
| EP3050023B1 (en) | 2014-10-27 | 2021-08-25 | Aseko, Inc. | Subcutaneous outpatient management |
| US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
| CN105030745A (zh) * | 2015-07-08 | 2015-11-11 | 南京医科大学 | 甘氨酸和二甲双胍的酰胺化产物在制备治疗糖尿病药物中的应用 |
| AU2016308953B2 (en) | 2015-08-20 | 2020-09-10 | Glytec, Llc | Diabetes management therapy advisor |
| DK3454907T3 (da) | 2016-06-03 | 2020-10-19 | Thetis Pharmaceuticals Llc | Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation |
| MX2019003725A (es) | 2016-09-30 | 2019-08-12 | Laboratorios Silanes S A De C V | Glicinato de metformina, composiciones farmaceuticas que comprenden la misma, y metodos de uso de la misma. |
| WO2018060962A2 (en) | 2016-09-30 | 2018-04-05 | Laboratorios Silanes S.A. De C.V. | Metformin amino acid compounds and methods of using the same |
| CN113105367B (zh) * | 2021-03-30 | 2022-08-02 | 广州大学 | 一类二甲双胍盐及其制备方法和应用 |
| CN114349665B (zh) * | 2021-11-30 | 2023-06-09 | 潍坊博创国际生物医药研究院 | 二甲双胍焦谷氨酸晶体及其制备方法与应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE568513A (es) | ||||
| FR2037002A1 (en) | 1969-04-30 | 1970-12-31 | Roques Bernard | N-substd biguanide pamoic acid salts prepn |
| DE1967138A1 (de) | 1969-07-17 | 1977-11-10 | Christian Brunnengraeber Chem | Therapeutisches mittel |
| AT325632B (de) | 1973-06-01 | 1975-10-27 | Hurka Wilhelm | Verfahren zur herstellung von nicotinsauren salzen von derivaten des biguanids |
| FR2243684B1 (es) | 1973-09-19 | 1977-01-28 | Semb | |
| CH602612A5 (es) | 1974-10-11 | 1978-07-31 | Hoffmann La Roche | |
| FR2320735A1 (fr) | 1975-08-12 | 1977-03-11 | Dabis Georges | Composition anti-cellulite |
| JPS57179494A (en) | 1981-04-30 | 1982-11-05 | Mitsubishi Plastics Ind | Method of closing through hole of pipe, circumferential wall thereof has through hole in pipe axial direction |
| FR2585572B3 (fr) | 1985-07-31 | 1987-12-31 | Hugelin Andre | Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse |
| DE793646T1 (de) * | 1994-11-23 | 1999-12-30 | Pharmacia & Upjohn Co., Kalamazoo | Carboxylierte aminoguanidine zum behandlung von insulin-unabhängigem diabetes mellitus |
| ES2216335T3 (es) | 1997-12-08 | 2004-10-16 | Bristol-Myers Squibb Company | Nuevas sales de metformina y procedimiento. |
| US6936275B2 (en) | 1999-12-20 | 2005-08-30 | Scolr, Inc. | Amino acid modulated extended release dosage form |
| WO2003068209A1 (en) * | 2002-02-14 | 2003-08-21 | Sonus Pharmaceuticals, Inc. | Metformin salts of lipophilic acids |
| US7181457B2 (en) * | 2003-05-28 | 2007-02-20 | Pervasive Software, Inc. | System and method for utilizing compression in database caches to facilitate access to database information |
| US20050163841A1 (en) | 2003-10-31 | 2005-07-28 | Wong Patrick S. | Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid |
| WO2005065675A1 (en) * | 2004-01-07 | 2005-07-21 | Premacs International Pty. Ltd. | Method of treatment |
| WO2006086856A1 (en) * | 2005-02-15 | 2006-08-24 | Messadek, Jallal | Combination therapeutic compositions and method of use |
| CA2650556A1 (en) * | 2005-04-27 | 2006-11-02 | Jallal Messadek | Insulins combinations |
| CA2691775A1 (en) * | 2006-06-16 | 2007-12-27 | Indigene Pharmaceuticals Inc. | Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications |
| NZ556735A (en) * | 2007-07-24 | 2009-03-31 | Vector Ltd | Securing devices and equipotential bonding system |
| DK2303838T3 (en) | 2008-06-26 | 2014-03-03 | Silanes Sa De Cv Lab | New metforminglycinatsalt for blood glucose control |
-
2008
- 2008-06-26 DK DK08807218.6T patent/DK2303838T3/en active
- 2008-06-26 HR HRP20140194AT patent/HRP20140194T1/hr unknown
- 2008-06-26 BR BRPI0822909A patent/BRPI0822909B8/pt active IP Right Grant
- 2008-06-26 CA CA2729035A patent/CA2729035C/en not_active Expired - Fee Related
- 2008-06-26 AU AU2008357111A patent/AU2008357111B2/en not_active Ceased
- 2008-06-26 WO PCT/IB2008/002665 patent/WO2009144527A1/en not_active Ceased
- 2008-06-26 MX MX2011000135A patent/MX2011000135A/es active IP Right Grant
- 2008-06-26 CN CN200880130084.3A patent/CN102159539B/zh active Active
- 2008-06-26 EP EP08807218.6A patent/EP2303838B1/en not_active Not-in-force
- 2008-06-26 ES ES08807218.6T patent/ES2450148T3/es active Active
- 2008-06-26 SI SI200831163T patent/SI2303838T1/sl unknown
- 2008-06-26 PL PL08807218T patent/PL2303838T3/pl unknown
- 2008-06-26 JP JP2011515639A patent/JP5551691B2/ja not_active Expired - Fee Related
- 2008-06-26 PT PT88072186T patent/PT2303838E/pt unknown
- 2008-06-26 KR KR1020117000071A patent/KR101522066B1/ko not_active Expired - Fee Related
-
2009
- 2009-06-25 PE PE2009000908A patent/PE20100257A1/es active IP Right Grant
- 2009-06-25 JO JO2009233A patent/JO2884B1/en active
- 2009-06-25 CL CL2009001484A patent/CL2009001484A1/es unknown
- 2009-06-26 AR ARP090102388A patent/AR074159A1/es unknown
- 2009-06-26 UY UY0001031945A patent/UY31945A/es not_active Application Discontinuation
-
2010
- 2010-12-23 NI NI201000234A patent/NI201000234A/es unknown
- 2010-12-24 US US12/928,985 patent/US8703183B2/en not_active Ceased
- 2010-12-24 EC EC2010010719A patent/ECSP10010719A/es unknown
- 2010-12-27 TN TNP2010000607A patent/TN2010000607A1/fr unknown
- 2010-12-27 MA MA33460A patent/MA32418B1/fr unknown
- 2010-12-27 TN TNP2010000604A patent/TN2010000604A1/fr unknown
-
2014
- 2014-02-25 CY CY20141100150T patent/CY1115098T1/el unknown
-
2016
- 2016-04-21 US US15/135,018 patent/USRE46496E1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY31945A (es) | Una nueva sal de glicinato de metformina para el control de la glucosa en sangre | |
| ECSP109979A (es) | Preparación sólida que contiene alogliptina y clorhidrato de metformina | |
| ES2537539T3 (es) | Composición oftálmica | |
| CL2012002526A1 (es) | Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca. | |
| ECSP11011121A (es) | Sales de fingolimod | |
| AR081060A1 (es) | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida | |
| CY1113873T1 (el) | Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90 | |
| NO20076592L (no) | Stabilt aktivt-stoffkompleks av salter av o-acetylsalicylsyre med basiske aminosyrer og glycin | |
| SV2010003770A (es) | Composicion y proceso- 356 | |
| AR075097A1 (es) | Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia | |
| MX2022001820A (es) | Sal y forma cristalina de un compuesto que tiene actividad agonista para el receptor 5 de esfingosina-1-fosfato [acido (2s,3r,4e)-2-amino-3-hidroxioctadeca-4-enil-1-fosforico (s1p5). | |
| ES2422161T3 (es) | Procedimiento para producir 1-(3,4-diclorobencil)-5-octilbiguanida o una sal de la misma | |
| AR080204A1 (es) | Procesos para preparar ciclopropilamidas e intermedios asociados con estas | |
| BR112012033030A2 (pt) | composição herbicida de sais de ácido picolínico | |
| ATE519737T1 (de) | Organische verbindungen | |
| EA201300249A1 (ru) | Способ обогащения соли аминосоединения | |
| UY34916A (es) | "preparación sólida que contiene ácido[(3s)-6-){2´,6´-dimetil-4´-[3-(metilsulfonil)propoxi]bifenil-3-il}metoxi)-2,3-dihidro-1-benzofuran-3-il]acético" | |
| AR055761A1 (es) | Procedimiento para preparar especies de aluminio | |
| DE602007013796D1 (de) | Ausstossflüssigkeit und ausstossverfahren | |
| BRPI0513935A (pt) | formulações de compostos de 2-amina-1,3-propanodiol | |
| AR067382A1 (es) | Soluciones oftalmicas estabilizadas | |
| ES2585558T3 (es) | Uso de sales de 3-carboxi-N-etil-N,N-dimetilpropan-1-aminio en el tratamiento de una enfermedad cardiovascular | |
| HN2010002738A (es) | Una nueva sal de glicinato de metformina para el control de la glucosa en sangre | |
| ECSP088088A (es) | Maleato de 3-[2-(dimetilamino)metil-(ciclohex-1-il)]fenol y sus formas cristalinas | |
| CO6331332A2 (es) | Una nueva sal de glicinato de metformina para el control de glucosa en sangre |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RDES | Application refused |
Effective date: 20200724 |